Week Ending April 26, 2021

Hepatitis C Is Common Among Trans Women in San Francisco
“Between 2011 and 2016, hepatitis C cases rose in the United States, largely affecting people who inject drugs, those who are incarcerated or unhoused and other marginalized groups. Oftentimes, trans women experience circumstances that increase their risk of contracting HIV or hepatitis C, such as being incarcerated or experiencing homelessness.”

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): Interim analysis of a two-stage, open-label, multicenter, single arm, phase 2/3 trial
“In patients with chronic HCV genotype 4 infection, efficacy as well as safety has been demonstrated by the combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, and sofosbuvir. In the STORM-C-1 trial, a two-stage, open-label, phase 2/3 single-arm clinical trial, the efficacy and safety of ravidasvir plus sofosbuvir were investigated in a diverse population of adults chronically infected with HCV.”

DAA Safe, Effective in Children with HCV Infection, Study Finds
“New data show a pediatric formulation of the direct-acting antiviral (DAAs) therapy glecaprevir/pibrentasvir (GLE/PIB) is highly effective and well-tolerated in pediatric patients with hepatitis C virus (HCV) infection.”

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma
“A 6-cm liver tumor in segment 8 was found in a woman, aged 36 years, with hepatitis C virus (HCV)–related cirrhosis. The tumor was initially noticed in a screening ultrasound and further characterization was done with a multiphase CT scan. The tumor showed arterial enhancement and venous washout, and hepatocellular carcinoma (HCC) was definitively diagnosed.”